Intriguingly, a number of studies from both breast cancer patients and mice have found a wild-type p53 status to be associated with an inferior clinical response to chemotherapy compared to tumors with mutant p53 [53],[54],[55],[56]. Here, TP53 is linked to breast carcinoma.